vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and N-able, Inc. (NABL). Click either name above to swap in a different company.
N-able, Inc. is the larger business by last-quarter revenue ($130.3M vs $83.5M, roughly 1.6× BillionToOne, Inc.). On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 11.8%). N-able, Inc. produced more free cash flow last quarter ($20.9M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
BLLN vs NABL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $130.3M |
| Net Profit | $5.7M | — |
| Gross Margin | 69.9% | 76.2% |
| Operating Margin | 11.5% | 10.2% |
| Net Margin | 6.8% | — |
| Revenue YoY | 117.4% | 11.8% |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $130.3M | ||
| Q3 25 | $83.5M | $131.7M | ||
| Q2 25 | — | $131.2M | ||
| Q1 25 | — | $118.2M | ||
| Q4 24 | $45.1M | $116.5M | ||
| Q3 24 | $38.4M | $116.4M | ||
| Q2 24 | — | $119.4M | ||
| Q1 24 | — | $113.7M |
| Q4 25 | — | — | ||
| Q3 25 | $5.7M | $1.4M | ||
| Q2 25 | — | $-4.0M | ||
| Q1 25 | — | $-7.2M | ||
| Q4 24 | $-11.5M | — | ||
| Q3 24 | $-14.9M | $10.8M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $7.5M |
| Q4 25 | — | 76.2% | ||
| Q3 25 | 69.9% | 77.5% | ||
| Q2 25 | — | 78.1% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | 57.1% | 80.0% | ||
| Q3 24 | 52.6% | 82.9% | ||
| Q2 24 | — | 84.0% | ||
| Q1 24 | — | 83.9% |
| Q4 25 | — | 10.2% | ||
| Q3 25 | 11.5% | 8.8% | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 17.0% | 13.7% | ||
| Q3 24 | -32.9% | 20.5% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 18.0% |
| Q4 25 | — | — | ||
| Q3 25 | 6.8% | 1.1% | ||
| Q2 25 | — | -3.1% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | -38.8% | 9.2% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 6.6% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | $0.10 | $0.01 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | $-1.13 | $0.01 | ||
| Q3 24 | $-1.47 | $0.06 | ||
| Q2 24 | — | $0.05 | ||
| Q1 24 | — | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $111.8M |
| Total DebtLower is stronger | $55.0M | $393.9M |
| Stockholders' EquityBook value | $-239.5M | $804.7M |
| Total Assets | $327.5M | $1.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $111.8M | ||
| Q3 25 | $195.2M | $101.4M | ||
| Q2 25 | — | $93.9M | ||
| Q1 25 | — | $94.1M | ||
| Q4 24 | $191.5M | $85.2M | ||
| Q3 24 | — | $174.4M | ||
| Q2 24 | — | $157.5M | ||
| Q1 24 | — | $139.2M |
| Q4 25 | — | $393.9M | ||
| Q3 25 | $55.0M | $331.7M | ||
| Q2 25 | — | $332.1M | ||
| Q1 25 | — | $332.6M | ||
| Q4 24 | $51.5M | $333.1M | ||
| Q3 24 | — | $333.6M | ||
| Q2 24 | — | $334.1M | ||
| Q1 24 | — | $334.5M |
| Q4 25 | — | $804.7M | ||
| Q3 25 | $-239.5M | $813.4M | ||
| Q2 25 | — | $809.4M | ||
| Q1 25 | — | $775.1M | ||
| Q4 24 | $-251.7M | $759.3M | ||
| Q3 24 | $-242.9M | $765.0M | ||
| Q2 24 | — | $724.4M | ||
| Q1 24 | — | $709.1M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | $327.5M | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $302.1M | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.46× | ||
| Q1 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $25.3M |
| Free Cash FlowOCF − Capex | $6.5M | $20.9M |
| FCF MarginFCF / Revenue | 7.7% | 16.0% |
| Capex IntensityCapex / Revenue | 8.8% | 3.4% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $75.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $25.3M | ||
| Q3 25 | $13.8M | $24.0M | ||
| Q2 25 | — | $24.2M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $26.0M | ||
| Q3 24 | — | $22.0M | ||
| Q2 24 | — | $27.3M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | — | $20.9M | ||
| Q3 25 | $6.5M | $17.4M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $18.8M | ||
| Q3 24 | — | $18.2M | ||
| Q2 24 | — | $24.0M | ||
| Q1 24 | — | $746.0K |
| Q4 25 | — | 16.0% | ||
| Q3 25 | 7.7% | 13.2% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 13.9% | ||
| Q4 24 | — | 16.2% | ||
| Q3 24 | — | 15.7% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | 8.8% | 5.0% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 17.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 2.89× | ||
| Q1 24 | — | 0.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
